



4D Molecular Therapeutics to Participate at Upcoming Investor Conferences

November 6, 2018

Emeryville, CA – November 6, 2018 – 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that company management will participate at the following upcoming investor conferences:

Conference Details:

Event: William Blair Biotech Focus Day
Date: Tuesday, November 13, 2018 at 10:05 a.m. PST
Location: San Francisco, CA

Event: Evercore ISI HealthconX
Date: Tuesday, November 27, 2018 at 9:05 a.m. EST
Location: Boston, MA

Event: Piper Jaffray Healthcare Conference
Date: Wednesday, November 28, 2018
Location: New York, NY

About 4D Molecular Therapeutics (4DMT)

4DMT is focused on the discovery and development of targeted, customized and proprietary next-generation AAV gene therapy products for use in patients with severe genetic diseases with high unmet medical need. Our robust discovery platform, termed Therapeutic Vector Evolution, empowers us to create customized gene delivery vehicles to deliver genes specifically to any tissue or organ in the body, by optimal clinical routes of administration, at lower doses and with resistance to pre-existing antibodies. These proprietary and targeted products allow us to treat both rare genetic diseases and complex large market diseases. 4DMT is creating a diverse and deep product pipeline through its own internal 4D products, as well as partnered programs.

About 4DMT's Therapeutic Vector Evolution

4DMT is advancing the field of targeted and optimized AAV vector technology by deploying principles of evolution and natural selection to create vectors that efficiently and selectively target the desired cells within the diseased human organ via clinically optimal routes of administration, at manageable doses and with resistance to pre-existing antibodies in the population. Our Therapeutic Vector Evolution platform deploys over 100 million unique AAV variants from over 35 unique and proprietary 4DMT AAV libraries with extensive diversity. After defining the Target Product Profile, and the associated Target Vector Profile, 4DMT then applies proprietary methods to identify lead vectors from within our AAV libraries. The result is a customized, novel, and proprietary pharmaceutical-grade product uniquely designed for targeted therapeutic gene delivery and efficacy in humans.

###

Contacts:

Media:

Jamie Firmage
jfirmage@4dmt.com
415-860-6301

Investors:

Pete Rahmer
Endurance Advisors
prahmer@enduranceadvisors.com
415-515-9763

Mike Zanoni
Endurance Advisors
mzanoni@enduranceadvisors.com
610-442-8570